Quick Links

Breadcrumbs Navigation

Home > Clinical Trials > Adult Clinical Trials - Gynecological Cancers - Ovarian cancer and cancers of the female organs

Jumbo Large Regular Text:

Print E-mail

Clinical Trials

Adult Clinical Trials - Gynecological Cancers - Ovarian cancer and cancers of the female organs

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Beatrice Nelson, RN at 919-684-3792.

Items 1 - 20 of 30

Integrated Dose Escalation for Advanced, Localized Cervical Cancer (The IDEAL Cervix Trial)
Principal Investigator: Junzo Chino
Phase: Phase I

GOG 0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Progression-Free Survival?
Principal Investigator: Laura Havrilesky
Phase: N/A
Phone: 919-684-9065

Tissue and Data Acquisition Activity for the Study of Gynecologic Disease
Principal Investigator: Laura Havrilesky
Phase: Other
Phone: 919-684-6125

A Randomized Phase II Evaluation of Carboplatin/Paclitaxel with and without Trastuzumab (Herceptin) in HER2/neu+ Patients with Advanced/Recurrent Uterine Serous Papillary Carcinoma
Principal Investigator: Laura Havrilesky
Phase: Phase II
Phone: 919-684-3792

A Phase II, Open -Label, Single-Arm, Non-Randomized, Multi-Center Study to Evaluate The Efficacy of Oral TKI258 as Second-Line Therapy in Patients with Either FGFR2 Mutated or Wild-Type Advanced and/or Metastatic Endometrial Cancer
Principal Investigator: Paula Lee
Phase: Phase II
Phone: 919-681-7471 or 919-684-3792

Cervical Cancer Detection Using Optical Spectroscopy
Principal Investigator: Nimmi Ramanujam
Phase: N/A
Phone: 919-660-8446

GOG 0273: Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Principal Investigator: Angeles Secord
Phase: N/A
Phone: 919-684-3792

A Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-7471

A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-681-7471

A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen For Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

BMS CA184-201: A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy Following Completion of Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects with Residual Measurable Disease
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-681-7471

GOG #187: Phase II Study of Paclitaxel for Ovarian Stromal Tumors As First-Line or Second-Line Therapy
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

GOG 0130F: A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in The Treatment of Recurrent or Persistent Carcinosarcoma of The Uterus
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

GOG 0186-I: A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab with Fosbretabulin Tromethamine (CA4P) (NSC #752293) in The Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

GOG 0254: A Phase II Evaluation of SU11248 (Sunitinib Malate) (IND# 74019, NSC# 736511) in The Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

GOG 0260- A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in The Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (Sponsor: GOG, IND# 110072)
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

GOG 0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. BLeomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of The Ovary
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

GOG 0268: A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864, IND# 61010) in Combination with Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First Line Therapy in The Treatment of Stage III-IV Clear Cell Carcinoma of The Ovary
Principal Investigator: Angeles Secord
Phase: Phase II
Phone: 919-684-3792

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Fallopian Tube and Peritoneal Primary Cancer
Principal Investigator: Angeles Secord
Phase: Phase III
Phone: 919-684-3792